Sudeep Pharma Restricted is launching its Preliminary Public Providing (IPO) to lift capital primarily for Capital expenditure for equipment on the Nandesari Facility I manufacturing line. The IPO contains a contemporary problem of 0.16 crore shares value Rs. 95 crore and a suggestion on the market of 1.35 crore shares value Rs. 800 crore, bringing the full problem measurement to Rs. 895 crore.
Sudeep Pharma Restricted IPO opens on November 21, 2025, and closes on November 25, 2025, with shares set to be listed on NSE and BSE on Friday November 28, 2025. Right here’s an entire overview of the problem.
Sudeep Pharma Restricted’s IPO is priced between Rs. 563 to Rs. 593 per share with quite a bit measurement of 25 shares. Retail funding is Rs. 14,825 (25 shares on the higher worth). For S-HNI, the funding is 14 tons (350 shares) totaling Rs. 2,07,550, and for B-HNI, a minimal of 68 tons (1,700 shares) totaling Rs. 10,08,100.
GMP of Sudeep Pharma Restricted IPO
As of November 20, 2025, the shares of Sudeep Pharma Restricted within the gray market had been buying and selling at a 19.39 % premium. The shares within the Gray Market traded at Rs. 708. This provides it a premium of Rs. 115 per share over the higher worth band of Rs. 593.
Overview of Sudeep Pharma Restricted
Sudeep Pharma Restricted, included in 1989, is a world producer of pharmaceutical excipients, food-grade minerals, and specialty diet substances, supplying over 200 merchandise to clients in additional than 100 international locations. The corporate operates six manufacturing services with a complete manufacturing capability of fifty,000 MT, specializing in key minerals akin to calcium, iron, magnesium, zinc, potassium, and sodium. It caters to various end-use sectors, together with prescribed drugs, meals, and diet.
Backed by sturdy R&D capabilities, Sudeep Pharma has in-house laboratories and pilot-scale services devoted to creating superior mineral salts and excipients. Its product portfolio spans pharmaceutical, meals and diet choices, specialty substances, and triturates. As of December 31, 2024, the corporate employed 704 everlasting employees.
Promoters of Sudeep Pharma Restricted
Sudeep Pharma Restricted’s promoters are Sujit Jaysukh Bhayani, Avani Sujit Bhayani, Shanil Sujit Bhayani, Sujeet Jaysukh Bhayani Huf, Riva Sources Non-public Restricted and Bhayani Household Belief, who collectively play a key position in guiding the corporate’s imaginative and prescient, technique, and development.
Sudeep Pharma Restricted Promoting Shareholders
The Sudeep Pharma Restricted IPO encompasses a important Supply for Sale, with promoters Sujit Jaysukh Bhayani promoting round 35.68 lakh fairness shares, Sujeet Jaysukh Bhayani HUF promoting round 84.19 lakh fairness shares, Shanil Sujit Bhayani promoting 7.5 lakh fairness shares and Avani Sujit Bhayani promoting round 7.54 lakh fairness shares every.
Lead Managers of Sudeep Pharma Restricted
ICICI Securities Restricted and IIFL Capital Providers Restricted are the book-running lead managers for the IPO. MUFG Intime India Non-public Restricted is the registrar dealing with the provide course of.
Goals of the IPO Supply
Sudeep Pharma Restricted intends to make use of the online proceeds from its IPO for 2 principal functions: round Rs. 75.81 crore to Capital expenditure in the direction of procurement of equipment for our manufacturing line positioned at Nandesari Facility I and remaining for common company functions.
Monetary Evaluation of Sudeep Pharma Restricted
Sudeep Pharma Restricted’s income from operations has elevated from Rs. 459.23 crore in FY24 to Rs. 502 crore in FY25, which represents a development of 9.31 %. The web revenue has elevated by 4.13 %, from Rs. 133.19 crore in FY24 to Rs. 138.69 crore in FY25.
The fundamental earnings per share elevated by 4.07 % and stood at Rs. 12.78 in FY25 as in opposition to Rs. 12.28 recorded in FY24. By way of return ratios, the corporate reviews a Return on Internet Value (RoNW) of 27.88 % and Debt to fairness stands at 0.20.
Strengths of Sudeep Pharma Restricted
- The corporate has established sturdy market management with a diversified portfolio of over 100 merchandise in a high-barrier trade.
- The corporate has a distinguished international buyer base, serving over 1,100 purchasers throughout areas, backed by long-standing partnerships that span many years.
- The corporate runs compliant, well-equipped vegetation in Gujarat and Eire with 72,246 MT annual capability throughout 68,446 sq. meters.
- The corporate has sturdy R&D capabilities, working one R&D centre with 33 specialists, finishing over 300 tasks and commercialising 106 merchandise during the last three years and as much as June 30, 2025.
Weaknesses of Sudeep Pharma Restricted
- The corporate’s manufacturing services bear common regulatory and buyer audits, and any high quality or compliance points may hurt its fame and enterprise efficiency.
- Any disruption or slowdown within the firm’s manufacturing or R&D operations may negatively impression its enterprise and monetary efficiency.
- A good portion of the corporate’s income comes from just a few key clients, and any loss or diminished demand from them may negatively impression its enterprise and financials.
- Failure to launch new merchandise on time or underperformance of commercialized merchandise may negatively impression the corporate’s enterprise and monetary outcomes.
- Delays or disruptions within the provide of uncooked supplies and gear may adversely have an effect on the corporate’s operations and monetary efficiency.
Conclusion
Sudeep Pharma Restricted’s IPO presents a chance to put money into a well-established pharmaceutical and specialty diet firm with a diversified product portfolio, sturdy international buyer base, and sturdy R&D capabilities. Whereas the corporate demonstrates regular monetary development and excessive return ratios, potential traders ought to contemplate operational, regulatory, and buyer focus dangers when evaluating the providing.
Written By Akshay Sanghavi
Disclaimer
The views and funding ideas expressed by funding specialists/broking homes/ranking businesses on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a threat of monetary losses. Buyers should subsequently train due warning whereas investing or buying and selling in shares. Commerce Brains Applied sciences Non-public Restricted or the writer should not answerable for any losses induced because of the choice primarily based on this text. Please seek the advice of your funding advisor earlier than investing.
